Shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) jumped in pre-market trading after AbbVie Inc. (NYSE:ABBV) announced it will acquire the company for a total equity value of approximately $8.7 billion.
AbbVie will acquire all outstanding shares of Cerevel for $45 per share in cash, with the transaction anticipated to close in the middle of 2024.
Cerevel Therapeutics shares rose 14.7% to $42.35 in pre-market trading.
Here are some other stocks moving in pre-market trading.
Gainers
Losers
Now Read This: Cramer's Top Auto Pick After 'Very Big Spike': 'By Far The Best Of The Group'
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
